In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Fibromyalgia is characterised by chronic widespread pain of unknown aetiology and affects approximately 2% of the population. It can cause significant patient disability, sizeable economic costs, complex management decisions and controversy for healthcare providers. In lieu of uniformly approved treatments for fibromyalgia, patients may try multiple pharmacological and non-pharmacological therapies with questionable efficacy. The literature lacks pharmacoeconomic studies that balance the cost and benefit of interventions. In the absence of this work, cost outcomes are reviewed in this paper. Due to inconclusive results, further study is needed on fibromyalgia treatment cost-effectiveness. These analyses could provide useful information for policy and evidence-based practice guidelines toward optimal disease management. Medical professionals should be a driving force in understanding the clinical and economic challenges of fibromyalgia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 2×
“In other studies, economic burden measures could have been evaluated through single items on the FIQ, Sheehan Disability Scale and Brief Pain Inventory, but were not mentioned [29,33,37-41].”
BackgroundMethodArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“, duloxetine [74], pregabalin [75], milnacipran [76], SPA treatments [77], acupuncture [78], home-based exercise [79], behavioural insomnia treatment [80]).”
BackgroundBennett, R. M., Kamin, M., Karim, R., & Rosenthal, N. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00116-5 · Cited by 403
Treatment of fibromyalgia with antidepressants: A meta-analysis
O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.06279.x · Cited by 340
Behavioral Insomnia Therapy for Fibromyalgia Patients: A Randomized Clinical Trial
Edinger, J. D., Wohlgemuth, W. K., Krystal, A. D., & Rice, J. R. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.21.2527 · Cited by 330 · cited 1×
“, duloxetine [74], pregabalin [75], milnacipran [76], SPA treatments [77], acupuncture [78], home-based exercise [79], behavioural insomnia treatment [80]).”
BackgroundArnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01089-0 · Cited by 261 · cited 1×
“Three studies included economic outcomes in the pharmacological treatment studies [32,35,36].”
BackgroundBiofeedback/relaxation training and exercise interventions for fibromyalgia: A prospective trial
Buckelew, S. P., Conway, R., Parker, J., Deuser, W. E., Read, J., Witty, T. E., Hewett, J. E., Minor, M., Johnson, J. C., Van Male, L., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/art.1790110307 · Cited by 258
A Double-blind Placebo Controlled Trial of Fluoxetine in Fibromyalgia
Wolfe, F., Cathey, M. A., & Hawley, D. J. (1994) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749409103725 · Cited by 252
A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia
Assefi, N. P., Sherman, K. J., Jacobsen, C., Goldberg, J., Smith, W. R., & Buchwald, D. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-1-200507050-00005 · Cited by 226 · cited 1×
“, duloxetine [74], pregabalin [75], milnacipran [76], SPA treatments [77], acupuncture [78], home-based exercise [79], behavioural insomnia treatment [80]).”
BackgroundVenlafaxine treatment of fibromyalgia
Sayar, K., Aksu, G., Ak, I., & Tosun, M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d112 · Cited by 157 · cited 1×
“In other studies, economic burden measures could have been evaluated through single items on the FIQ, Sheehan Disability Scale and Brief Pain Inventory, but were not mentioned [29,33,37-41].”
Method
Cited by
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Häuser, W., Klose, P., Langhorst, J., Moradi, B., Steinbach, M., Schiltenwolf, M., & Busch, A. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3002 · Cited by 436
“In addition, reference sections of original studies, systematic reviews [8-10] and evidencebased guidelines on the management of FMS [4-6] were screened manually.”
BackgroundHäuser, W., Bernardy, K., Arnold, B., Offenbächer, M., & Schiltenwolf, M. (2009) · Arthritis Care & Research · doi:10.1002/art.24276 · Cited by 378
Guidelines on the management of fibromyalgia syndrome – A systematic review
Häuser, W., Thieme, K., & Turk, D. C. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.01.006 · Cited by 347
Treatment of Fibromyalgia Syndrome With Antidepressants: A Meta-analysis
Häuser, W., Bernardy, K., Üçeyler, N., & Sommer, C. (2009) · JAMA · doi:10.1001/jama.2008.944 · Cited by 338
Metadata
- Authors
- Robinson, R. L., & Jones, M. L.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2006-05-24
- Volume
- 7
- Issue
- 8
- Pages
- 1027-1039
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1976913296
- Cited by
- 46
- References
- 12
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. https://app.cochat.ai/papers/10.1517/14656566.7.8.1027
- The paper
- Robinson, R. L., & Jones, M. L. (2006). In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.7.8.1027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.